Supplements

boswellia decreases osteoarthritis pain

In plain terms: Does boswellia (frankincense) help arthritis and joint pain?

Strong support Supplements 💰 Industry COI noted

RefutedContestedStrong support

consensus score 0.79

Yes — it's one of the better-proven herbal joint remedies. Multiple trials find standardized boswellia extract eases knee-osteoarthritis pain and stiffness about as well as anti-inflammatory drugs, often with gentler effects on the stomach.

📅 Last reviewed: 2026-07-15 ⓘ

Evidence ladder

How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."

Top evidence so far: All trials, pooled (Meta-analysis)

MechanismIn-vitroAnimalObservationalRCTMeta-analysis

How the studies fall

9 support 0 contradict 0 tested null 2 mixed · 11 sources, 9 independent groups · 1 superseded — pooled inside a review, counted once

What the evidence shows

Boswellia's standout claim, and it's well-earned: multiple independent meta-analyses of RCTs find standardized Boswellia serrata extract (often the AKBA-enriched forms Aflapin/5-Loxin) reduces knee-osteoarthritis pain and improves function, with a favourable safety profile versus NSAIDs. One of the better-evidenced herbal joint remedies.

Cochrane agrees with us see how our grade compares ▾

Cochrane review 2014 · high-quality evidence (Boswellia arm: 2 studies, 85 participants) Agrees with our grade

Small total sample; the review's headline conclusion emphasises the ASU product. Boswellia-specific effect sizes need the full text.

“Oral herbal therapies for treating osteoarthritis (Cochrane CD002947.pub2, 2014). Meta-analysis was restricted to Boswellia serrata (monoherbal) and avocado-soyabean unsaponifiables. Five studies of three Boswellia serrata extracts were included; 'High-quality evidence from two studies (85 participants) indicated that 90 days treatment with 100 mg of enriched Boswellia' improved osteoarthritis outcomes.”

Why we agree: we reached the same direction independently, from our own appraisal of 11 sources. Two methods landing in the same place is a stronger signal than either alone.

What is Cochrane, and why trust it?

Cochrane produces systematic reviews: instead of running a new study, they gather every trial ever done on a question, judge how well each was run, and pool the results. They take no commercial or industry funding, which is why the medical community treats their reviews as a gold standard — and why we check our own verdicts against theirs.

About Cochrane ↗ · Get involved / support ↗

Read the Cochrane review ↗

The evidence (14)

Source	Grade	Stance	Quality	Finding
Kimmatkar N, Thawani V, Hingorani L, Khiyani R 2003 · Phytomedicine	RCT	supports	moderate	Landmark RCT: Boswellia serrata extract reduced knee pain and improved function/walking versus placebo.
Du P, Ajia A, Xiang Z, Zheng S, Hu C, Wang P 2025 · Frontiers in nutrition	meta-analysis	supports	moderate	Network meta-analysis of 22 RCTs/2777 participants comparing dietary supplements for knee OA via WOMAC; Aflapin (a Boswellia serrata extract) ranked among the most effective interventions specifically for reducing WOMAC pain subscore vs pla
Kumar B, Ghaytidak AB, Pandey AK, Somepalli RR, Sarda P, Raychaudhuri SP, Rokkam MP 2025 · Journal of the American Nutrition Association	RCT	supports	moderate	80 adults with Kellgren-Lawrence II-III knee OA, 180-day RCT of Boswellia serrata extract SN13108F (Aflapin, 100mg/day) vs placebo; WOMAC, VAS and Lequesne scores significantly reduced (p<0.001) and MRI showed increased cartilage volume/thi
Majeed M, Majeed S, Narayanan NK, Nagabhushanam K 2019 · Phytother Res	RCT	supports	moderate	Double-blind RCT (Boswellin/AKBA): reduced OA pain and improved physical function with good tolerability. ↩ SUPERSEDED — pooled in the review above, counted once
d10-12775-qs-2026-56-72067 2026 · Quality in Sport	observational	supports	moderate	Structured narrative review of Boswellia serrata phytochemistry/mechanisms/clinical evidence in OA/RA; reports standardised extracts produce 'clinically meaningful reductions in WOMAC and VAS scores in knee OA,' citing a Cochrane synthesis
Zhang Y, Gui Y, Adams R, Farragher J, Itsiopoulos C, Bow K, Cai M, Han J 2025 · Nutrients	meta-analysis	supports	moderate	Comparative-effectiveness meta-analysis of knee-OA supplements: Boswellia showed significant symptom benefit.
Dalmonte T, Andreani G, Rudelli C, Isani G 2024 · Phytother Res	meta-analysis	mixed	moderate	Meta-analysis: Boswellia oleogum-resin extracts significantly reduced pain and improved function in knee osteoarthritis.
Dubey V, Kheni D, Sureja V 2024 · Explore (NY)	RCT	supports	moderate	RCT (standardized Aflapin extract): improved OA pain and function versus placebo.
Inprasit C, Bunyamahote S, Boonpattharatthiti K, Thimkorn P, Intakhiao S, Dhippayom T 2026 · Complementary therapies in medicine	meta-analysis	mixed	moderate	Systematic review + network meta-analysis, 20 RCTs/1633 participants comparing Curcuma longa (CL) and Boswellia serrata (BS) in knee OA; modified BS formulations showed significant improvement in WOMAC pain, stiffness and function vs compar
Bannuru RR, Osani MC, Al-Eid F, Wang C 2018 · Semin Arthritis Rheum	meta-analysis	supports	high	SR+meta-analysis: both curcumin and Boswellia were efficacious for knee-OA pain/function versus placebo.
Yu G, Xiang W, Zhang T, Zeng L, Yang K, Li J 2020 · BMC Complement Med Ther	meta-analysis	supports	moderate	Systematic review: Boswellia and its extracts improved OA pain, stiffness and function.
Liu X, Machado GC, Eyles JP, Ravi V, Hunter DJ 2018 · Br J Sports Med	meta-analysis	supports	moderate	Systematic review with random-effects meta-analysis and meta-regression (NOT a network meta-analysis, as previously recorded here): 'An intervention systematic review with random effects meta-analysis and meta-regression', 69 eligible RCTs of 20 oral supplements vs placebo in hand, hip or knee OA. 'Boswellia serrata extract' is named among the seven supplements that 'demonstrated large (effect size >0.80) and clinically important effects for pain reduction at short term'; 'Similar results were found for physical function.' DENOMINATOR: the 69 studies span all 20 supplements - the abstract reports no per-supplement trial count, participant count or effect estimate, so the Boswellia subset's own denominator is the available text does not say. DURATION: short term only - 'No supplements were identified with clinically important effects on pain reduction at long term', and Boswellia is not among the two supplements ('green-lipped mussel extract and undenatured type II collagen') with clinically important medium-term pain effects. Quality moderate, not high: the authors' reliability statement lands on exactly this large-effect group - 'Some supplements with a limited number of studies and participants suggested large treatment effects' - and 'The Grading of Recommendations Assessment, Development and Evaluation suggested a wide range of quality evidence from very low to high'. Abstract-grade (Br J Sports Med is not in the PMC open-access subset).
Jayaram M, Kim J, Baek KS, Jung H, Kim J, M K P, T S C, H B S, Ramaiah V, S P 2025 · Journal of medicinal food	RCT	supports	moderate	150 adults with non/mild knee OA, randomized double-blind placebo-controlled, Boswellia serrata extract BOSMAX 90 days; WOMAC total decreased significantly vs placebo/baseline (-24.55 at day 90, p<0.05), VAS and Lequesne also improved, TNF
Park D, Koh HS, Choi YH, Moon JW, Park I 2026 · Nutrients	observational	supports	moderate	Structured narrative review (SANRA-informed, dual-independent selection, no meta-analysis of its own; PubMed/Embase/Cochrane, Jan 2000 - Mar 2026) re-passing Yu et al. 2020 on Boswellia serrata in osteoarthritis: 'Conventional and standardized boswellia extracts have shown statistically significant improvements in VAS pain, WOMAC pain, stiffness, and function compared with placebo, with pooled mean differences indicating moderate short-term symptomatic benefit, such as a WOMAC pain mean difference of approximately -14 points'. Authors' own limitations, which are part of the finding: 'effect estimates vary widely across trials, heterogeneity is frequently high, and overall certainty is limited by methodological constraints, including risk of bias and industry sponsorship in a substantial proportion of studies', supporting 'a cautious interpretation of Boswellia as a possible short-term symptom-modulating adjunct rather than a consistently reproducible analgesic intervention'. Typical exposure ~100-250 mg/day standardised (AKBA-enriched) extract, oral, ~4-12 weeks. No structural disease modification and no randomised physical-performance data in KOA (off-object; recorded as candidates). retained: the underlying synthesis is already the vault's own source s32680575 (Yu 2020), so counting this review would double-count it.

Disagree, or know a study we missed?

We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.

📚 Suggest a study ⚑ Flag / request reclassification

Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).

Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.